Combination chaperonin 10 and beta-interferon therapy for multiple sclerosis

2:

• The method of claim 1, when used as a treatment to prevent relapse of MS.

3:

• The method of claim 1, wherein IFN-β and cpn10 are administered together.

4:

• The method of claim 1, wherein IFN-β and cpn10 are administered separately.

5:

• The method of claim 3, wherein IFN-β and cpn10 are administered by injection.

6:

• The method of claim 4, wherein cpn10 is administered orally.

7:

• The method of claim 4, wherein IFN-β is administered by injection.

8:

• The method of claim 1, wherein the pharmaceutically effective amount of cpn10 and IFN-β comprises 5-60 mg of cpn10 .

9:

• The method of claim 8, wherein the pharmaceutically-effective amount of cpn10 and IFN-β comprises 10-30 mg of cpn10 .

10:

• The method of claim 1, wherein the pharmaceutically-effective amount of cpn10 and IFN-β comprises 1-10 Million International Units (MIU) of IFN-β.

11:

• The method of claim 10, wherein the pharmaceutically-effective amount of cpn10 and IFN-β comprises 4-6 MIU of IFN-β.

12:

• A pharmaceutical composition for treating MS, said composition comprising a pharmaceutically-effective amount of cpn10 and IFN-β and a pharmaceutically-acceptable carrier or diluent.

13:

• The composition of claim 12, wherein the pharmaceutically-effective amount of cpn10 and IFN-β comprises 5-60 mg of cpn10, or comprises 10-30 mg of cpn10 .

(canceled)

15:

• The composition of claim 12, wherein the pharmaceutically-effective amount of cpn10 and IFN-β comprises 1-10 MIU of IFN-β, or comprises 4-6 MIU of IFN-β.

(canceled)

17:

• A kit comprising a pharmaceutically-effective amount of cpn10 and IFN-β and a pharmaceutically-acceptable carrier or diluent.

18:

• The kit of claim 17, wherein said IFN-1 is in dehydrated form, which in use, is rehydrated by said pharmaceutically-acceptable carrier or diluent.

19:

• The kit of claim 18, wherein said cpn10 is in dehydrated form and in use, is rehydrated by said pharmaceutically-acceptable carrier or diluent.

20:

• The kit of claim 17, wherein said cpn10 is in tablet or capsule form.

21:

• The kit of claim 17, wherein the pharmaceutically-effective amount of cpn10 and IFN-β comprises 5-60 mg of cpn10, or comprises 10-30 mg of cpn10 .

(canceled)

23:

• The kit of claim 17, wherein the pharmaceutically-effective amount of cpn10 and IFN-β comprises 1-10 MIU of IFN-β, or comprises 4-6 MIU of IFN-β.

(canceled)